Special Issue

Ligand Targeted Nano-Medicine: Current Status and Translational Opportunity

Message from the Guest Editors

Receptor-targeted and ligand-guided nano-medicine-based drug and gene delivery therapies have shown promise for the diagnosis, prevention and treatment of human ailments. Ligand targeted nano delivery systems have resulted in the site specific delivery of therapeutics to improve efficacy while reducing adverse effects because of reduced exposure to normal healthy cells. Specifically, nano or macroparticle-based drugs and genes have great potential in revolutionizing the therapeutic delivery field. Despite recent advances, translational applications of newer drug and gene delivery technologies to the clinic have a lower success rate. Therefore, there is an unmet need to address the critical aspects and gaps for translational application of these delivery systems. This Special Issue will address the current status in the development of ligand-targeted drug and gene delivery systems and their translational application for the diagnosis and treatment of the human diseases. targeted delivery; nanoformulations; site specificity; ligand targeting; biomaterial; nanoparticles; nanocarriers; antibody–drug conjugate; immunoliposomes

Guest Editors

Dr. Priyanka Bhatt

Department of Pharmaceutical Sciences, Wegmans School of Pharmacy, St. John Fisher College, 3690 East Avenue, Room # RCW107, Rochester, NY 14618, USA

Dr. Vijaykumar B. Sutariya

Taneja College of Pharmacy, USF Health, University of South Florida, Tampa, FL 33612, USA

Deadline for manuscript submissions

closed (30 July 2021)

Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed

mdpi.com/si/75871

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics

Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed

mdpi.com/journal/pharmaceutics

MDPI

About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).